These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2265 related items for PubMed ID: 19585728

  • 1. Irritable bowel syndrome: a mild disorder; purely symptomatic treatment.
    Prescrire Int; 2009 Apr; 18(100):75-9. PubMed ID: 19585728
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Review article: the safety profile of tegaserod.
    Schoenfeld P.
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():25-30. PubMed ID: 15521852
    [Abstract] [Full Text] [Related]

  • 7. The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study.
    Bardhan KD, Forbes A, Marsden CL, Mason T, Short G.
    Aliment Pharmacol Ther; 2004 Jul 15; 20(2):213-22. PubMed ID: 15233702
    [Abstract] [Full Text] [Related]

  • 8. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P, Dapoigny M, Bonaz B, Siproudhis L.
    Aliment Pharmacol Ther; 2005 Feb 15; 21(4):435-44. PubMed ID: 15709995
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Common gastrointestinal symptoms: irritable bowel syndrome.
    Fashner J, Gitu AC.
    FP Essent; 2013 Oct 15; 413():16-23. PubMed ID: 24124703
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome.
    Shah E, Kim S, Chong K, Lembo A, Pimentel M.
    Am J Med; 2012 Apr 15; 125(4):381-93. PubMed ID: 22444104
    [Abstract] [Full Text] [Related]

  • 16. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
    Krause R, Ameen V, Gordon SH, West M, Heath AT, Perschy T, Carter EG.
    Am J Gastroenterol; 2007 Aug 15; 102(8):1709-19. PubMed ID: 17509028
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Treatment of irritable bowel syndrome.
    Trinkley KE, Nahata MC.
    J Clin Pharm Ther; 2011 Jun 15; 36(3):275-82. PubMed ID: 21545610
    [Abstract] [Full Text] [Related]

  • 19. Potential future therapies for irritable bowel syndrome: will disease modifying therapy as opposed to symptomatic control become a reality?
    Spiller RC.
    Gastroenterol Clin North Am; 2005 Jun 15; 34(2):337-54. PubMed ID: 15862939
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 114.